CD34 and acute myeloid leukemia: NPM1 mutations are usually associated with absence of HLA-DR and CD34 expression [11]; however, the surface marker expression in blasts varies in individual AML patients and the clinical implication of immunophenotype in this subtype of AML remains unclear.